The components have their own evidence, but there is no established human evidence proving that this exact blend works as a combination. Direct combination evidence is shown separately when it exists.
Still uncertain: Human benefit, whether the components work better together, safety, route, ratio or dosing for the three-way blend.
By confirming your subscription, you agree to receive occasional WhichPeps Evidence Updates. Kit processes the signup and email delivery for WhichPeps. Privacy. Unsubscribe anytime.
What does the evidence mean in simple terms? table
What is it?
Multi-peptide blend
Entity type
Peptide blend
Research focus
Skin/tissue-repair/recovery claims
Human evidence
No direct controlled human trial of the GHK-Cu + BPC-157 + TB-500 three-component blend was identified; evidence must be assessed component by component.
Regulatory status
No approved medicine corresponding to this blend was identified.
Main limitations
Human efficacy, synergy, safety, route, ratio or dosing for the three-way blend.
Safety
Unknown blend interactions and purity; component-specific safety limitations remain.
Evidence reviewed
2026-09-18
i
No direct controlled human trial of the GHK-Cu + BPC-157 + TB-500 three-component blend was identified; evidence must be assessed component by component.
Outcome-level evidence
Evidence is not one score.
This section separates the evidence status from what the evidence actually found. Direct combination evidence is never inferred from component studies.
Does the GHK-Cu + BPC-157 + TB-500 three-way blend have direct clinical evidence?
Evidence gap
Documented evidence gap — component/partial-stack evidence only
Search conclusion: No direct controlled human trial of the three-component blend identified. A BPC-157 + TB-500 rat study does not validate adding GHK-Cu.
Public wording rule: Show each component evidence plus the BPC/TB preclinical combination result; label the three-way blend as untested clinically.
Evidence rule: absence of direct combination evidence is a research conclusion when the search has been documented; it is not permission to infer efficacy from the components.
Evidence synthesis
✓No direct controlled human trial of the three-component GHK-Cu + BPC-157 + TB-500 blend was identified. The available evidence is component-level plus a BPC-157/TB-500 rat combination study.
!The BPC-157/TB-500 animal result does not establish that adding GHK-Cu is beneficial or safe.
Selected study & evidence records
No structured study detail is currently rendered for this page.
Safety and unknowns
Unknown blend interactions and purity; component-specific safety limitations remain.
Technical details
Mechanism / biologyA multi-compound blend combining GHK-Cu, BPC-157 and TB-500 is marketed in some research markets. There is no validated combined clinical mechanism or interaction profile; evidence must be assessed component by component.
Route / formulation boundaryBlend composition, ratio, route and manufacturing quality vary between products. Component literature does not establish the efficacy or safety of the mixture.
Identity / data-quality noteThe BPC-157 + TB-500 rat combination study does not validate the addition of GHK-Cu.
Study / label regimen evidenceStudy-regimen evidence reviewed. No clinical regimen for the GHK-Cu + BPC-157 + TB-500 blend identified; individual-component evidence cannot establish a combined dose.
WhichPeps does not rely on a single headline study when the evidence base is broader. Primary research, registries, regulators and supporting records are kept distinct.
0structured study records
0outcome records
4linked source records
How to read these counts: they show evidence coverage, not evidence strength. One large, well-designed study can be more informative than several weak or indirect records.
Show supporting and discovery sources
Study pages above contain the records used for public evidence summaries. The links below include supporting, regulatory and literature-discovery sources; a registry or search result is not treated as proof of benefit.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
